Why are Dysfunctional Checkpoints a Therapeutic Target?
Targeting dysfunctional checkpoints presents a promising therapeutic strategy. Drugs that can restore the function of these checkpoints or exploit their weaknesses have the potential to selectively kill cancer cells while sparing normal cells. For example, PARP inhibitors are effective against cancers with BRCA1/2 mutations, as they exploit the defective DNA repair mechanisms in these cells.
